Granzyme serine proteases in inflammation and rheumatic diseases.

Joeckel, L. T. & Bird, P. I. Are all granzymes cytotoxic in vivo? Biol. Chem. 395, 181–202 (2014).

doi: 10.1515/hsz-2013-0238 pubmed: 24002663

Voskoboinik, I., Whisstock, J. C. & Trapani, J. A. Perforin and granzymes: function, dysfunction and human pathology. Nat. Rev. Immunol. 15, 388–400 (2015).

doi: 10.1038/nri3839 pubmed: 25998963

Cullen, S. P., Adrain, C., Lüthi, A. U., Duriez, P. J. & Martin, S. J. Human and murine granzyme B exhibit divergent substrate preferences. J. Cell Biol. 176, 435–444 (2007).

pmcid: 2063979 doi: 10.1083/jcb.200612025 pubmed: 17283187

Kaiserman, D. et al. The major human and mouse granzymes are structurally and functionally divergent. J. Cell Biol. 175, 619–630 (2006).

pmcid: 2064598 doi: 10.1083/jcb.200606073 pubmed: 17116752

Pardo, J. et al. Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs. Cell Death Differ. 15, 567–579 (2008).

doi: 10.1038/sj.cdd.4402289 pubmed: 18064039

Thomas, D. A., Scorrano, L., Putcha, G. V., Korsmeyer, S. J. & Ley, T. J. Granzyme B can cause mitochondrial depolarization and cell death in the absence of BID, BAX, and BAK. Proc. Natl Acad. Sci. USA 98, 14985–14990 (2001).

pmcid: 64970 doi: 10.1073/pnas.261581498 pubmed: 11752447

Sánchez-Martínez, D. et al. Human NK cells activated by EBV

pmcid: 4404803 doi: 10.4161/2162402X.2014.991613 pubmed: 25949911

Plasman, K., Demol, H., Bird, P. I., Gevaert, K. & Van Damme, P. Substrate specificities of the granzyme tryptases A and K. J. Proteome Res. 13, 6067–6077 (2014).

doi: 10.1021/pr500968d pubmed: 25383893

Plasman, K. et al. Conservation of the extended substrate specificity profiles among homologous granzymes across species. Mol. Cell Proteom. 12, 2921–2934 (2013).

doi: 10.1074/mcp.M113.028670

Garzón-Tituaña, M. et al. Granzyme A inhibition reduces inflammation and increases survival during abdominal sepsis. Theranostics 11, 3781–3795 (2021).

pmcid: 7914344 doi: 10.7150/thno.49288 pubmed: 33664861

Metkar, S. S. et al. Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 29, 720–733 (2008).

doi: 10.1016/j.immuni.2008.08.014 pubmed: 18951048

Hagn, M. et al. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J. Immunol. 183, 1838–1845 (2009).

doi: 10.4049/jimmunol.0901066 pubmed: 19592644

Hink-Schauer, C., Estébanez-Perpiñá, E., Kurschus, F. C., Bode, W. & Jenne, D. E. Crystal structure of the apoptosis-inducing human granzyme A dimer. Nat. Struct. Biol. 10, 535–540 (2003).

doi: 10.1038/nsb945 pubmed: 12819770

Bell, J. K. et al. The oligomeric structure of human granzyme A is a determinant of its extended substrate specificity. Nat. Struct. Biol. 10, 527–534 (2003).

doi: 10.1038/nsb944 pubmed: 12819769

Lieberman, J. Granzyme A activates another way to die. Immunol. Rev. 235, 93–104 (2010).

pmcid: 2905780 doi: 10.1111/j.0105-2896.2010.00902.x pubmed: 20536557

Pardo, J. et al. The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. Microbes Infect. 11, 452–459 (2009).

doi: 10.1016/j.micinf.2009.02.004 pubmed: 19249384

Beresford, P. J. et al. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J. Biol. Chem. 276, 43285–43293 (2001).

doi: 10.1074/jbc.M108137200 pubmed: 11555662

Zhou, Z. et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368, eaaz7548 (2020).

doi: 10.1126/science.aaz7548 pubmed: 32299851

Liu, X., Xia, S., Zhang, Z., Wu, H. & Lieberman, J. Channelling inflammation: gasdermins in physiology and disease. Nat. Rev. Drug Discov. 20, 384–405 (2021).

pmcid: 7944254 doi: 10.1038/s41573-021-00154-z pubmed: 33692549

Isaaz, S., Baetz, K., Olsen, K., Podack, E. & Griffiths, G. M. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur. J. Immunol. 25, 1071–1079 (1995).

doi: 10.1002/eji.1830250432 pubmed: 7737276

Nakamura, K., Arahata, K., Ishiura, S., Osame, M. & Sugita, H. Degradative activity of granzyme A on skeletal muscle proteins in vitro: a possible molecular mechanism for muscle fiber damage in polymyositis. Neuromuscul. Dis. 3, 303–310 (1993).

doi: 10.1016/0960-8966(93)90023-D

Campbell, R. A. et al. Granzyme A in human platelets regulates the synthesis of proinflammatory cytokines by monocytes in aging. J. Immunol. 200, 295–304 (2018).

doi: 10.4049/jimmunol.1700885 pubmed: 29167233

Arias, M. A. et al. Elucidating sources and roles of granzymes A and B during bacterial infection and sepsis. Cell Rep. 8, 420–429 (2014).

doi: 10.1016/j.celrep.2014.06.012 pubmed: 25017060

Santiago, L. et al. Extracellular granzyme A promotes colorectal cancer development by enhancing gut inflammation. Cell Rep. 32, 107847 (2020).

doi: 10.1016/j.celrep.2020.107847 pubmed: 32640217

Santiago, L. et al. Granzyme A contributes to inflammatory arthritis in mice through stimulation of osteoclastogenesis. Arthritis Rheumatol. 69, 320–334 (2017).

doi: 10.1002/art.39857 pubmed: 27598995

Masson, D. & Tschopp, J. Inhibition of lymphocyte protease granzyme A by antithrombin III. Mol. Immunol. 25, 1283–1289 (1988).

doi: 10.1016/0161-5890(88)90043-0 pubmed: 3266293

Simon, M. M., Tran, T., Fruth, U., Gurwitz, D. & Kramer, M. D. Regulation of mouse T cell associated serine proteinase-1 (MTSP-1) by proteinase inhibitors and sulfated polysaccharides. Biol. Chem. Hoppe Seyler 371, 81–87 (1990).

pubmed: 1976012

Kaiserman, D. et al. Identification of serpinb6b as a species-specific mouse granzyme A inhibitor suggests functional divergence between human and mouse granzyme A. J. Biol. Chem. 289, 9408–9417 (2014).

pmcid: 3979379 doi: 10.1074/jbc.M113.525808 pubmed: 24505135

Aybay, E. et al. Extended cleavage specificities of human granzymes A and K, two closely related enzymes with conserved but still poorly defined functions in T and NK cell-mediated immunity. Front. Immunol. 14, 1211295 (2023).

pmcid: 10366535 doi: 10.3389/fimmu.2023.1211295 pubmed: 37497217

Boivin, W. A., Cooper, D. M., Hiebert, P. R. & Granville, D. J. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab. Invest. 89, 1195–1220 (2009).

pmcid: 7102238 doi: 10.1038/labinvest.2009.91 pubmed: 19770840

Thornberry, N. A. et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B: functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272, 17907–17911 (1997).

doi: 10.1074/jbc.272.29.17907 pubmed: 9218414

Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020).

pmcid: 7123794 doi: 10.1038/s41586-020-2071-9 pubmed: 32188940

Aubert, A., Lane, M., Jung, K. & Granville, D. J. Granzyme B as a therapeutic target: an update in 2022. Expert Opin. Ther. Targets 26, 979–993 (2022).

doi: 10.1080/14728222.2022.2161890 pubmed: 36542784

Richardson, K. C., Jung, K., Pardo, J., Turner, C. T. & Granville, D. J. Noncytotoxic roles of granzymes in health and disease. Physiology 37, 323–348 (2022).

doi: 10.1152/physiol.00011.2022 pubmed: 35820180

Prakash, M. D., Bird, C. H. & Bird, P. I. Active and zymogen forms of granzyme B are constitutively released from cytotoxic lymphocytes in the absence of target cell engagement. Immunol. Cell Biol. 87, 249–254 (2009).

doi: 10.1038/icb.2008.98 pubmed: 19079360

Jung, K., Pawluk, M. A., Lane, M., Nabai, L. & Granville, D. J. Granzyme B in epithelial barrier dysfunction and related skin diseases. Am. J. Physiol. Cell Physiol. 323, C170–c189 (2022).

doi: 10.1152/ajpcell.00052.2022 pubmed: 35442832

Skjelland, M. et al. Plasma levels of granzyme B are increased in patients with lipid-rich carotid plaques as determined by echogenicity. Atherosclerosis 195, e142–e146 (2007).

doi: 10.1016/j.atherosclerosis.2007.05.001 pubmed: 17568588

Tak, P. P. et al. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 116, 366–370 (1999).

pmcid: 1905268 doi: 10.1046/j.1365-2249.1999.00881.x pubmed: 10337032

Hodge, S., Hodge, G., Nairn, J., Holmes, M. & Reynolds, P. N. Increased airway granzyme B and perforin in current and ex-smoking COPD subjects. COPD 3, 179–187 (2006).

doi: 10.1080/15412550600976868 pubmed: 17361498

Hiroyasu, S. et al. Granzyme B inhibition reduces disease severity in autoimmune blistering diseases. Nat. Commun. 12, 302 (2021).

pmcid: 7804321 doi: 10.1038/s41467-020-20604-3 pubmed: 33436591

Malmestrom, C. et al. Relapses in multiple sclerosis are associated with increased CD8

doi: 10.1016/j.jneuroim.2008.03.001 pubmed: 18396337

Turner, C. T. et al. Granzyme B contributes to barrier dysfunction in oxazolone-induced skin inflammation through E-cadherin and FLG cleavage. J. Invest. Dermatol. 141, 36–47 (2021).

doi: 10.1016/j.jid.2020.05.095 pubmed: 32504614

Turner, C. T. et al. Granzyme B mediates impaired healing of pressure injuries in aged skin. NPJ Aging Mech. Dis. 7, 6 (2021).

pmcid: 7935969 doi: 10.1038/s41514-021-00059-6 pubmed: 33674592

Russo, V. et al. Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction. Sci. Rep. 8, 9690 (2018).

pmcid: 6018769 doi: 10.1038/s41598-018-28070-0 pubmed: 29946113

Kurschus, F. C. et al. Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett. 562, 87–92 (2004).

doi: 10.1016/S0014-5793(04)00187-5 pubmed: 15044006

Tremblay, G. M., Wolbink, A. M., Cormier, Y. & Hack, C. E. Granzyme activity in the inflamed lung is not controlled by endogenous serine proteinase inhibitors. J. Immunol. 165, 3966–3969 (2000).

doi: 10.4049/jimmunol.165.7.3966 pubmed: 11034405

Buzza, M. S. et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J. Biol. Chem. 280, 23549–23558 (2005).

doi: 10.1074/jbc.M412001200 pubmed: 15843372

Prakash, M. D. et al. Granzyme B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling. Immunity 41, 960–972 (2014).

doi: 10.1016/j.immuni.2014.11.012 pubmed: 25526309

Chamberlain, C. M. et al. Perforin-independent extracellular granzyme B activity contributes to abdominal aortic aneurysm. Am. J. Pathol. 176, 1038–1049 (2010).

pmcid: 2808106 doi: 10.2353/ajpath.2010.090700 pubmed: 20035050

Ang, L. S. et al. Serpina3n attenuates granzyme B-mediated decorin cleavage and rupture in a murine model of aortic aneurysm. Cell Death Dis. 2, e209 (2011).

pmcid: 3186906 doi: 10.1038/cddis.2011.88 pubmed: 21900960

Hiebert, P. R. et al. Granzyme B contributes to extracellular matrix remodeling and skin aging in apolipoprotein E knockout mice. Exp. Gerontol. 46, 489–499 (2011).

doi: 10.1016/j.exger.2011.02.004 pubmed: 21316440

Boivin, W. A. et al. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-β1. PLoS One 7, e33163 (2012).

pmcid: 3316562 doi: 10.1371/journal.pone.0033163 pubmed: 22479366

Hendel, A. & Granville, D. J. Granzyme B cleavage of fibronectin disrupts endothelial cell adhesion, migration and capillary tube formation. Matrix Biol. 32, 14–22 (2013).

doi: 10.1016/j.matbio.2012.11.013 pubmed: 23228447

Hiebert, P. R., Wu, D. & Granville, D. J. Granzyme B degrades extracellular matrix and contributes to delayed wound closure in apolipoprotein E knockout mice. Cell Death Differ. 20, 1404–1414 (2013).

pmcid: 3770318 doi: 10.1038/cdd.2013.96 pubmed: 23912712

Hendel, A., Hsu, I. & Granville, D. J. Granzyme B releases vascular endothelial growth factor from extracellular matrix and induces vascular permeability. Lab. Invest. 94, 716–725 (2014).

pmcid: 4074428 doi: 10.1038/labinvest.2014.62 pubmed: 24791744

Parkinson, L. G. et al. Granzyme B mediates both direct and indirect cleavage of extracellular matrix in skin after chronic low-dose ultraviolet light irradiation. Aging Cell 14, 67–77 (2015).

doi: 10.1111/acel.12298 pubmed: 25495009

Shen, Y. et al. Topical small molecule granzyme B inhibitor improves remodeling in a murine model of impaired burn wound healing. Exp. Mol. Med. 50, 1–11 (2018).

doi: 10.1038/s12276-018-0095-0 pubmed: 29849046

Matsubara, J. A. et al. Retinal distribution and extracellular activity of granzyme B: a serine protease that degrades retinal pigment epithelial tight junctions and extracellular matrix proteins. Front. Immunol. 11, 574 (2020).

pmcid: 7155911 doi: 10.3389/fimmu.2020.00574 pubmed: 32318066

Obasanmi, G. et al. Granzyme B contributes to choroidal neovascularization and age-related macular degeneration through proteolysis of thrombospondin-1. Lab. Invest. 103, 100123 (2023).

doi: 10.1016/j.labinv.2023.100123 pubmed: 36849037

Ronday, H. K. et al. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Rheumatology 40, 55–61 (2001).

doi: 10.1093/rheumatology/40.1.55 pubmed: 11157142

Froelich, C. J. et al. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J. Immunol. 151, 7161–7171 (1993).

doi: 10.4049/jimmunol.151.12.7161 pubmed: 8258716

Buzza, M. S. et al. Antihemostatic activity of human granzyme B mediated by cleavage of von Willebrand factor. J. Biol. Chem. 283, 22498–22504 (2008).

doi: 10.1074/jbc.M709080200 pubmed: 18577516

Qian, Q. et al. Maternal diesel particle exposure promotes offspring asthma through NK cell-derived granzyme B. J. Clin. Invest. 130, 4133–4151 (2020).

pmcid: 7410053 pubmed: 32407293

Loeb, C. R. K., Harris, J. L. & Craik, C. S. Granzyme B proteolyzes receptors important to proliferation and survival, tipping the balance toward apoptosis. J. Biol. Chem. 281, 28326–28335 (2006).

doi: 10.1074/jbc.M604544200 pubmed: 16798735

Shen, Y. et al. Granzyme B deficiency protects against angiotensin II-induced cardiac fibrosis. Am. J. Pathol. 186, 87–100 (2016).

doi: 10.1016/j.ajpath.2015.09.010 pubmed: 26610869

Afonina, I. S. et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol. Cell 44, 265–278 (2011).

pmcid: 3319689 doi: 10.1016/j.molcel.2011.07.037 pubmed: 22017873

Omoto, Y. et al. Granzyme B is a novel interleukin-18 converting enzyme. J. Dermatol. Sci. 59, 129–135 (2010).

doi: 10.1016/j.jdermsci.2010.05.004 pubmed: 20621450

Lim, Y. S. et al. NK cell-derived extracellular granzyme B drives epithelial ulceration during HSV-2 genital infection. Cell Rep. 42, 112410 (2023).

doi: 10.1016/j.celrep.2023.112410 pubmed: 37071533

Hu, M. D. et al. γδ intraepithelial lymphocytes facilitate pathological epithelial cell shedding via CD103-mediated granzyme release. Gastroenterology 162, 877–889.e877 (2022).

doi: 10.1053/j.gastro.2021.11.028 pubmed: 34861219

Casciola-Rosen, L., Andrade, F., Ulanet, D., Wong, W. B. & Rosen, A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J. Exp. Med. 190, 815–826 (1999).

pmcid: 2195625 doi: 10.1084/jem.190.6.815 pubmed: 10499920

Darrah, E. & Rosen, A. Granzyme B cleavage of autoantigens in autoimmunity. Cell Death Differ. 17, 624–632 (2010).

doi: 10.1038/cdd.2009.197 pubmed: 20075942

Darrah, E. et al. Proteolysis by granzyme B enhances presentation of autoantigenic peptidylarginine deiminase 4 epitopes in rheumatoid arthritis. J. Proteome Res. 16, 355–365 (2017).

doi: 10.1021/acs.jproteome.6b00617 pubmed: 27700100

Haddad, P. et al. Structure and evolutionary origin of the human granzyme H gene. Int. Immunol. 3, 57–66 (1991).

doi: 10.1093/intimm/3.1.57 pubmed: 2049336

Wang, L. et al. Structural insights into the substrate specificity of human granzyme H: the functional roles of a novel RKR motif. J. Immunol. 188, 765–773 (2012).

doi: 10.4049/jimmunol.1101381 pubmed: 22156497

Sedelies, K. A. et al. Discordant regulation of granzyme H and granzyme B expression in human lymphocytes. J. Biol. Chem. 279, 26581–26587 (2004).

doi: 10.1074/jbc.M312481200 pubmed: 15069086

Rönnberg, E. et al. Granzyme H is a novel protease expressed by human mast cells. Int. Arch. Allergy Immunol. 165, 68–74 (2014).

doi: 10.1159/000368403 pubmed: 25342632

Waterhouse, N. J. & Trapani, J. A. H is for helper: granzyme H helps granzyme B kill adenovirus-infected cells. Trends Immunol. 28, 373–375 (2007).

doi: 10.1016/j.it.2007.08.001 pubmed: 17766182

Romero, V., Fellows, E., Jenne, D. E. & Andrade, F. Cleavage of La protein by granzyme H induces cytoplasmic translocation and interferes with La-mediated HCV-IRES translational activity. Cell Death Differ. 16, 340–348 (2009).

doi: 10.1038/cdd.2008.165 pubmed: 19039329

Yu, D. et al. Natural killer cells disrupt nerve fibers by granzyme H in atheriosclerotic cerebral small vessel disease. J. Gerontol. A Biol. Sci. Med. Sci. 78, 414–423 (2023).

doi: 10.1093/gerona/glac173 pubmed: 36006802

Bovenschen, N. et al. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. J. Biol. Chem. 284, 3504–3512 (2009).

doi: 10.1074/jbc.M806716200 pubmed: 19059912

Hink-Schauer, C. et al. The 2.2-A crystal structure of human pro-granzyme K reveals a rigid zymogen with unusual features. J. Biol. Chem. 277, 50923–50933 (2002).

doi: 10.1074/jbc.M207962200 pubmed: 12384499

Bratke, K., Kuepper, M., Bade, B., Virchow, J. C. Jr & Luttmann, W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8

doi: 10.1002/eji.200526122 pubmed: 16106370

Duquette, D. et al. Human granzyme K Is a feature of innate T cells in blood, tissues, and tumors, responding to cytokines rather than TCR stimulation. J. Immunol. 211, 633–647 (2023).

doi: 10.4049/jimmunol.2300083 pubmed: 37449888

Bade, B. et al. Detection of soluble human granzyme K in vitro and in vivo. Eur. J. Immunol. 35, 2940–2948 (2005).

doi: 10.1002/eji.200526249 pubmed: 16208762

Rucevic, M. et al. Altered levels and molecular forms of granzyme K in plasma from septic patients. Shock 27, 488–493 (2007).

doi: 10.1097/01.shk.0000246905.24895.e5 pubmed: 17438453

Li, T., Yang, C., Jing, J., Sun, L. & Yuan, Y. Granzyme K — a novel marker to identify the presence and rupture of abdominal aortic aneurysm. Int. J. Cardiol. 338, 242–247 (2021).

doi: 10.1016/j.ijcard.2021.06.014 pubmed: 34139229

Bratke, K. et al. Granzyme K: a novel mediator in acute airway inflammation. Thorax 63, 1006–1011 (2008).

doi: 10.1136/thx.2007.091215 pubmed: 18559365

Joeckel, L. T. et al. Mouse granzyme K has pro-inflammatory potential. Cell Death Differ. 18, 1112–1119 (2011).

pmcid: 3131959 doi: 10.1038/cdd.2011.5 pubmed: 21311565

Turner, C. T. et al. Granzyme K expressed by classically activated macrophages contributes to inflammation and impaired remodeling. J. Invest. Dermatol. 139, 930–939 (2019).

doi: 10.1016/j.jid.2018.09.031 pubmed: 30395844

Sharma, M. et al. Extracellular granzyme K mediates endothelial activation through the cleavage of protease-activated receptor-1. FEBS J. 283, 1734–1747 (2016).

doi: 10.1111/febs.13699 pubmed: 26936634

Kaiserman, D. et al. Granzyme K initiates IL-6 and IL-8 release from epithelial cells by activating protease-activated receptor 2. PLoS One 17, e0270584 (2022).

pmcid: 9321427 doi: 10.1371/journal.pone.0270584 pubmed: 35881628

Jonsson, A. H. et al. Granzyme K

pmcid: 9972878 doi: 10.1126/scitranslmed.abo0686 pubmed: 35704599

Turner, C. T. et al. Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation. Br. J. Dermatol. 189, 279–291 (2023).

doi: 10.1093/bjd/ljac017 pubmed: 36652225

Mogilenko, D. A. et al. Comprehensive profiling of an aging immune system reveals clonal GZMK

doi: 10.1016/j.immuni.2020.11.005 pubmed: 33271118

Verschoor, C. P. et al. NK- and T-cell granzyme B and K expression correlates with age, CMV infection and influenza vaccine-induced antibody titres in older adults. Front. Aging 3, 1098200 (2022).

doi: 10.3389/fragi.2022.1098200 pubmed: 36685324

Tyrrell, D. J. et al. Clonally expanded memory CD8

doi: 10.1038/s43587-023-00515-w pubmed: 37996758

Fernandez, D. M. et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 25, 1576–1588 (2019).

pmcid: 7318784 doi: 10.1038/s41591-019-0590-4 pubmed: 31591603

Cai, Y. et al. Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion. J. Exp. Med. 219, e20211777 (2022).

pmcid: 8789099 doi: 10.1084/jem.20211777 pubmed: 35061012

Xu, T. et al. Single-cell profiling reveals pathogenic role and differentiation trajectory of granzyme K

pmcid: 10243796 doi: 10.1172/jci.insight.167490 pubmed: 36881472

Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902–914 (2019).

pmcid: 6726437 doi: 10.1038/s41590-019-0398-x pubmed: 31209404

Dunlap, G. S. et al. Single-cell transcriptomics reveals distinct effector profiles of infiltrating T cells in lupus skin and kidney. JCI Insight 7, e156341 (2022).

pmcid: 9089784 doi: 10.1172/jci.insight.156341 pubmed: 35290245

de Poot, S. A. H. et al. Human and mouse granzyme M display divergent and species-specific substrate specificities. Biochem. J. 437, 431–442 (2011).

doi: 10.1042/BJ20110210 pubmed: 21564021

Sayers, T. J. et al. The restricted expression of granzyme M in human lymphocytes. J. Immunol. 166, 765–771 (2001).

doi: 10.4049/jimmunol.166.2.765 pubmed: 11145648

de Poot, S. A. & Bovenschen, N. Granzyme M: behind enemy lines. Cell Death Differ. 21, 359–368 (2014).

pmcid: 3921602 doi: 10.1038/cdd.2013.189 pubmed: 24413154

Pao, L. I. et al. Functional analysis of granzyme M and its role in immunity to infection. J. Immunol. 175, 3235–3243 (2005).

doi: 10.4049/jimmunol.175.5.3235 pubmed: 16116214

Anthony, D. A. et al. A role for granzyme M in TLR4-driven inflammation and endotoxicosis. J. Immunol. 185, 1794–1803 (2010).

doi: 10.4049/jimmunol.1000430 pubmed: 20585036

Baschuk, N. et al. NK cell intrinsic regulation of MIP-1ɑ by granzyme M. Cell Death Dis. 5, e1115 (2014).

pmcid: 3973215 doi: 10.1038/cddis.2014.74 pubmed: 24625974

Nordstrom, D. C. et al. Granzyme A-immunoreactive cells in synovial fluid in reactive and rheumatoid arthritis. Clin. Rheumatol. 11, 529–532 (1992).

doi: 10.1007/BF02283113 pubmed: 1283120

Smeets, T. J., Dolhain, R. J., Breedveld, F. C. & Tak, P. P. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J. Pathol. 186, 75–81 (1998).

doi: 10.1002/(SICI)1096-9896(199809)186:1<75::AID-PATH142>3.0.CO;2-B pubmed: 9875143

Qiao, J. et al. Elevated serum granzyme B levels are associated with disease activity and joint damage in patients with rheumatoid arthritis. J. Int. Med. Res. 48, 0300060520962954 (2020).

pmcid: 7780569 doi: 10.1177/0300060520962954 pubmed: 33143503

Goldbach-Mansky, R. et al. Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis. Ann. Rheum. Dis. 64, 715–721 (2005).

doi: 10.1136/ard.2003.007039 pubmed: 15471892

Knevel, R. et al. A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Rheuma. 65, 582–589 (2013).

doi: 10.1002/art.37808

Colombo, E., Scarsi, M., Piantoni, S., Tincani, A. & Airo, P. Serum levels of granzyme B decrease in patients with rheumatoid arthritis responding to abatacept. Clin. Exp. Rheumatol. 34, 37–41 (2016).

pubmed: 26633185

Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928–942 (2019).

pmcid: 6602051 doi: 10.1038/s41590-019-0378-1 pubmed: 31061532

Moon, J.-S. et al. Cytotoxic CD8

pmcid: 9852471 doi: 10.1038/s41467-022-35264-8 pubmed: 36658110

Tak, P. P. et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum. 37, 1735–1743 (1994).

doi: 10.1002/art.1780371205 pubmed: 7986219

Kim, W. J., Kim, H., Suk, K. & Lee, W. H. Macrophages express granzyme B in the lesion areas of atherosclerosis and rheumatoid arthritis. Immunol. Lett. 111, 57–65 (2007).

doi: 10.1016/j.imlet.2007.05.004 pubmed: 17604848

Xu, L. et al. Impairment of granzyme B-producing regulatory B cells correlates with exacerbated rheumatoid arthritis. Front. Immunol. 8, 768 (2017).

pmcid: 5491972 doi: 10.3389/fimmu.2017.00768 pubmed: 28713386

Cui, D. et al. Changes in regulatory B cells and their relationship with rheumatoid arthritis disease activity. Clin. Exp. Med. 15, 285–292 (2015).

doi: 10.1007/s10238-014-0310-9 pubmed: 25245953

Kageyama, Y., Kobayashi, H., Kato, N. & Shimazu, M. Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis. Mod. Rheumatol. 19, 372–378 (2009).

doi: 10.3109/s10165-009-0175-z pubmed: 19458908

Horiuchi, K., Saito, S., Sasaki, R., Tomatsu, T. & Toyama, Y. Expression of granzyme B in human articular chondrocytes. J. Rheumatol. 30, 1799–1810 (2003).

pubmed: 12913938

Darrah, E. et al. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci. Transl. Med. 5, 186ra165 (2013).

doi: 10.1126/scitranslmed.3005370

Halvorsen, E. H. et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann. Rheum. Dis. 67, 414–417 (2008).

doi: 10.1136/ard.2007.080267 pubmed: 18006540

Kinloch, A. et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum. 58, 2287–2295 (2008).

doi: 10.1002/art.23618 pubmed: 18668562

Luo, Y. et al. The minor collagens in articular cartilage. Protein Cell 8, 560–572 (2017).

pmcid: 5546929 doi: 10.1007/s13238-017-0377-7 pubmed: 28213717

Weng, S. S. H. et al. Sensitive determination of proteolytic proteoforms in limited microscale proteome samples. Mol. Cell Proteom. 18, 2335–2347 (2019).

doi: 10.1074/mcp.TIR119.001560

Zhou, J., Tang, X., Ding, Y., An, Y. & Zhao, X. Natural killer cell activity and frequency of killer cell immunoglobulin-like receptors in children with different forms of juvenile idiopathic arthritis. Pediatr. Allergy Immunol. 24, 691–696 (2013).

doi: 10.1111/pai.12130 pubmed: 24112428

Wang, M. et al. Single-cell analysis in blood reveals distinct immune cell profiles in gouty arthritis. J. Immunol. 210, 745–752 (2023).

doi: 10.4049/jimmunol.2200422 pubmed: 36705528

Canete, J. D. et al. Distinct synovial immunopathology in Behcet disease and psoriatic arthritis. Arthritis Res. Ther. 11, R17 (2009).

pmcid: 2688249 doi: 10.1186/ar2608 pubmed: 19196489

Shan, L. et al. Increased intra-articular granzyme M may trigger local IFN-λ1/IL-29 response in rheumatoid arthritis. Clin. Exp. Rheumatol. 38, 220–226 (2020).

doi: 10.55563/clinexprheumatol/ffb107 pubmed: 31172927

McLoughlin, R. M. et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl Acad. Sci. USA 102, 9589–9594 (2005).

pmcid: 1172246 doi: 10.1073/pnas.0501794102 pubmed: 15976028

Young, L. H. et al. Expression of cytolytic mediators by synovial fluid lymphocytes in rheumatoid arthritis. Am. J. Pathol. 140, 1261–1268 (1992).

pmcid: 1886510 pubmed: 1580335

Kummer, J. A. et al. Expression of granzymes A and B in synovial tissue from patients with rheumatoid arthritis and osteoarthritis. Clin. Immunol. Immunopathol. 73, 88–95 (1994).

doi: 10.1006/clin.1994.1173 pubmed: 7923921

Nanki, T. et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 46, 2878–2883 (2002).

doi: 10.1002/art.10622 pubmed: 12428227

Jaime, P. et al CD56

doi: 10.1016/j.joca.2017.06.007 pubmed: 28668542

Wilson, J. A. et al. RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation. PLoS Pathog. 13, e1006155 (2017).

pmcid: 5312928 doi: 10.1371/journal.ppat.1006155 pubmed: 28207896

Jia, T. et al. CRISPR/Cas13d targeting GZMA in PARs pathway regulates the function of osteoclasts in chronic apical periodontitis. Cell Mol. Biol. Lett. 28, 70 (2023).

pmcid: 10464397 doi: 10.1186/s11658-023-00477-2 pubmed: 37626297

Simon, M. M., Kramer, M. D., Prester, M. & Gay, S. Mouse T-cell associated serine proteinase 1 degrades collagen type IV: a structural basis for the migration of lymphocytes through vascular basement membranes. Immunology 73, 117–119 (1991).

pmcid: 1384528 pubmed: 2045125

Simon, M. M., Prester, M., Nerz, G., Kramer, M. D. & Fruth, U. Release of biologically active fragments from human plasma-fibronectin by murine T cell-specific proteinase 1 (TSP-1). Biol. Chem. Hoppe Seyler 369, 107–112 (1988).

pubmed: 3060134

Crow, M. K. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann. Rheum. Dis. 82, 999–1014 (2023).

doi: 10.1136/ard-2022-223741 pubmed: 36792346

Shah, D., Kiran, R., Wanchu, A. & Bhatnagar, A. Soluble granzyme B and cytotoxic T lymphocyte activity in the pathogenesis of systemic lupus erythematosus. Cell Immunol. 269, 16–21 (2011).

doi: 10.1016/j.cellimm.2011.03.004 pubmed: 21458778

Kok, H. M. et al. Systemic and local granzyme B levels are associated with disease activity, kidney damage and interferon signature in systemic lupus erythematosus. Rheumatology 56, 2129–2134 (2017).

doi: 10.1093/rheumatology/kex332 pubmed: 28968826

Chen, L. et al. IKZF1 polymorphisms are associated with susceptibility, cytokine levels, and clinical features in systemic lupus erythematosus. Medicine 99, e22607 (2020).

pmcid: 7544280 doi: 10.1097/MD.0000000000022607 pubmed: 33031316

Daca, A. et al. Two systemic lupus erythematosus (SLE) global disease activity indexes — the SLE disease activity index and the systemic lupus activity measure —demonstrate different correlations with activation of peripheral blood CD4

doi: 10.1016/j.humimm.2011.08.005 pubmed: 21906646

Blanco, P. et al. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 52, 201–211 (2005).

doi: 10.1002/art.20745 pubmed: 15641052

Patel, J. et al. Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient response to antimalarials. Arthritis Rheumatol. 74, 1687–1698 (2022).

doi: 10.1002/art.42235 pubmed: 35583812

Abdou, A. G., Shoeib, M., Bakry, O. A. & El-Bality, H. Immunohistochemical expression of granzyme B and perforin in discoid lupus erythematosus. Ultrastruct. Pathol. 37, 408–416 (2013).

doi: 10.3109/01913123.2013.816400 pubmed: 23980805

Fogagnolo, L. et al. Cytotoxic granules in distinct subsets of cutaneous lupus erythematosus. Clin. Exp. Dermatol. 39, 835–839 (2014).

doi: 10.1111/ced.12428 pubmed: 25214407

Wenzel, J. et al. CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. J. Am. Acad. Dermatol. 56, 648–650 (2007).

doi: 10.1016/j.jaad.2006.08.014 pubmed: 17367614

Wenzel, J. et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br. J. Dermatol. 153, 1011–1015 (2005).

doi: 10.1111/j.1365-2133.2005.06784.x pubmed: 16225615

Grassi, M., Capello, F., Bertolino, L., Seia, Z. & Pippione, M. Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin. Exp. Dermatol. 34, 910–914 (2009).

doi: 10.1111/j.1365-2230.2009.03297.x pubmed: 19456762

Lovato, B. H. et al. IL-1β and IL-17 in cutaneous lupus erythematous skin biopsies: could immunohistochemicals indicate a tendency towards systemic involvement? Bras. Dermatol. 99, 66–71 (2023).

doi: 10.1016/j.abd.2023.02.007

Zhou, M. et al. JAK/STAT signaling controls the fate of CD8

doi: 10.1016/j.jaut.2020.102424 pubmed: 32085893

Litvinova, E. et al. MAIT cells altered phenotype and cytotoxicity in lupus patients are linked to renal disease severity and outcome. Front. Immunol. 14, 1205405 (2023).

pmcid: 10598677 doi: 10.3389/fimmu.2023.1205405 pubmed: 37885889

Murayama, G. et al. A critical role for mucosal-associated invariant T cells as regulators and therapeutic targets in systemic lupus erythematosus. Front. Immunol. 10, 2681 (2019).

pmcid: 6895065 doi: 10.3389/fimmu.2019.02681 pubmed: 31849932

Perez, R. K. et al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science 376, eabf1970 (2022).

pmcid: 9297655 doi: 10.1126/science.abf1970 pubmed: 35389781

Hernandez-Pigeon, H. et al. UVA induces granzyme B in human keratinocytes through MIF: implication in extracellular matrix remodeling. J. Biol. Chem. 282, 8157–8164 (2007).

doi: 10.1074/jbc.M607436200 pubmed: 17224449

van Leeuwen, E. M. et al. Emergence of a CD4

doi: 10.4049/jimmunol.173.3.1834 pubmed: 15265915

Aguilera, J. et al. Granzymes, IL-16, and poly(ADP-ribose) polymerase 1 increase during wildfire smoke exposure. J. Allergy Clin. Immunol. Glob. 2, 100093 (2023).

pmcid: 10399148 doi: 10.1016/j.jacig.2023.100093 pubmed: 37539354

Tsokos, G. C., Lo, M. S., Costa Reis, P. & Sullivan, K. E. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 12, 716–730 (2016).

doi: 10.1038/nrrheum.2016.186 pubmed: 27872476

Lu, C. et al. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. J. Immunother. Cancer 7, 157 (2019).

pmcid: 6589175 doi: 10.1186/s40425-019-0635-8 pubmed: 31228946

Newby, B. N. et al. Type 1 interferons potentiate human CD8

pmcid: 5697952 doi: 10.2337/db17-0106 pubmed: 28877912

Turner, C. T., Lim, D. & Granville, D. J. Granzyme B in skin inflammation and disease. Matrix Biol. 75–76, 126–140 (2019).

doi: 10.1016/j.matbio.2017.12.005 pubmed: 29247692

Graham, K. L. et al. Granzyme B is dispensable for immunologic tolerance to self in a murine model of systemic lupus erythematosus. Arthritis Rheum. 52, 1684–1693 (2005).

doi: 10.1002/art.21092 pubmed: 15934098

Rabani, M. et al. IL-21 dependent granzyme B production of B-cells is decreased in patients with lupus nephritis. Clin. Immunol. 188, 45–51 (2018).

doi: 10.1016/j.clim.2017.12.005 pubmed: 29274388

Bai, M. et al. Impaired granzyme B-producing regulatory B cells in systemic lupus erythematosus. Mol. Immunol. 140, 217–224 (2021).

doi: 10.1016/j.molimm.2021.09.012 pubmed: 34749262

Brito-Zeron, P. et al. Sjögren syndrome. Nat. Rev. Dis. Prim. 2, 16047 (2016).

doi: 10.1038/nrdp.2016.47 pubmed: 27383445

Kaneko, N. et al. Cytotoxic CD8

pmcid: 9475031 doi: 10.1038/s41598-022-19397-w pubmed: 36104369

Akiyama, M., Yoshimoto, K. & Kaneko, Y. Significant association of CX3CR1+CD8 T cells with aging and distinct clinical features in Sjögren’s syndrome and IgG4-related disease. Clin. Exp. Rheumatol. 41, 2409–2417 (2023).

pubmed: 37812481

Tasaki, S. et al. Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren’s syndrome. Ann. Rheum. Dis. 76, 1458–1466 (2017).

doi: 10.1136/annrheumdis-2016-210788 pubmed: 28522454

Wang, Q. et al. Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome. Arthritis Res. Ther. 23, 257 (2021).

pmcid: 8507116 doi: 10.1186/s13075-021-02632-6 pubmed: 34641948

Huang, M. et al. Detection of apoptosis-specific autoantibodies directed against granzyme B-induced cleavage fragments of the SS-B (La) autoantigen in sera from patients with primary Sjögren’s syndrome. Clin. Exp. Immunol. 142, 148–154 (2005).

pmcid: 1809481 doi: 10.1111/j.1365-2249.2005.02888.x pubmed: 16178869

Pope, J. E. et al. State-of-the-art evidence in the treatment of systemic sclerosis. Nat. Rev. Rheumatol. 19, 212–226 (2023).

pmcid: 9970138 doi: 10.1038/s41584-023-00909-5 pubmed: 36849541

Fuschiotti, P., Medsger, T. A. Jr & Morel, P. A. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum. 60, 1119–1128 (2009).

doi: 10.1002/art.24432 pubmed: 19333920

Ayano, M. et al. Increased CD226 expression on CD8

doi: 10.4049/jimmunol.1403046 pubmed: 26109642

Padilla, C. M. et al. Increased CD8

doi: 10.1093/rheumatology/kead273

Maehara, T. et al. Cytotoxic CD4

pmcid: 7190971 doi: 10.1172/JCI131700 pubmed: 31990684

Gumkowska-Sroka, O. et al. Cytometric characterization of main immunocompetent cells in patients with systemic sclerosis: relationship with disease activity and type of immunosuppressive treatment. J. Clin. Med. 8, 625 (2019).

pmcid: 6571868 doi: 10.3390/jcm8050625 pubmed: 31071980

Horikawa, M. et al. Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J. Invest. Dermatol. 125, 731–737 (2005).

doi: 10.1111/j.0022-202X.2005.23767.x pubmed: 16185273

Henriques, A. et al. Subset-specific alterations in frequencies and functional signatures of γδ T cells in systemic sclerosis patients. Inflamm. Res. 65, 985–994 (2016).

doi: 10.1007/s00011-016-0982-6 pubmed: 27576328

Kahaleh, M. B., Fan, P. S. & Otsuka, T. γδ Receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin. Immunol. 91, 188–195 (1999).

doi: 10.1006/clim.1999.4694 pubmed: 10227811

Schachna, L. et al. Recognition of granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum. 46, 1873–1884 (2002).

doi: 10.1002/art.10407 pubmed: 12124872

Ulanet, D. B., Flavahan, N. A., Casciola-Rosen, L. & Rosen, A. Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: insights into the association of specific autoantibodies with distinct disease phenotypes. Arthritis Rheum. 50, 233–241 (2004).

doi: 10.1002/art.11485 pubmed: 14730621

Overall, C. M. & Dean, R. A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 25, 69–75 (2006).

doi: 10.1007/s10555-006-7890-0 pubmed: 16680573

Sipione, S. et al. Identification of a novel human granzyme B inhibitor secreted by cultured Sertoli cells. J. Immunol. 177, 5051–5058 (2006).

doi: 10.4049/jimmunol.177.8.5051 pubmed: 17015688

Horvath, A. J. et al. The murine orthologue of human antichymotrypsin: a structural paradigm for clade A3 serpins. J. Biol. Chem. 280, 43168–43178 (2005).

doi: 10.1074/jbc.M505598200 pubmed: 16141197

Hsu, I. et al. Serpina3n accelerates tissue repair in a diabetic mouse model of delayed wound healing. Cell Death Dis. 5, e1458 (2014).

pmcid: 4237249 doi: 10.1038/cddis.2014.423 pubmed: 25299783

Li, F. et al. Neuronal serpina3n is an endogenous protector against blood brain barrier damage following cerebral ischemic stroke. J. Cereb. Blood Flow. Metab. 43, 241–257 (2023).

doi: 10.1177/0271678X221113897 pubmed: 36457151

Haile, Y. et al. Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo. J. Neuroinflammation 12, 157 (2015).

pmcid: 4558826 doi: 10.1186/s12974-015-0376-7 pubmed: 26337722

Saito, A. et al. Blockade of granzyme B remarkably improves mucocutaneous diseases with keratinocyte death in interface dermatitis. J. Invest. Dermatol. 138, 2079–2083 (2018).

doi: 10.1016/j.jid.2018.03.1507 pubmed: 29577918

Raveney, B. J. E. et al. Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat. Commun. 6, 8437 (2015).

doi: 10.1038/ncomms9437 pubmed: 26436530

Uranga-Murillo, I. et al. Biological relevance of granzymes A and K during E. coli sepsis. Theranostics 11, 9873–9883 (2021).

pmcid: 8581435 doi: 10.7150/thno.59418 pubmed: 34815792

Sas, G., Pepper, D. S. & Cash, J. D. Investigations on antithrombin III in normal plasma and serum. Br. J. Haematol. 30, 265–272 (1975).

doi: 10.1111/j.1365-2141.1975.tb00541.x pubmed: 1201212

Willoughby, C. A. et al. Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. Bioorg. Med. Chem. Lett. 12, 2197–2200 (2002).

doi: 10.1016/S0960-894X(02)00363-3 pubmed: 12127536

Dufour, A. & Overall, C. M. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol. Sci. 34, 233–242 (2013).

doi: 10.1016/j.tips.2013.02.004 pubmed: 23541335

Ebnet, K. et al. Granzyme A-deficient mice retain potent cell-mediated cytotoxicity. EMBO J. 14, 4230–4239 (1995).

pmcid: 394506 doi: 10.1002/j.1460-2075.1995.tb00097.x pubmed: 7556064

Heusel, J. W., Wesselschmidt, R. L., Shresta, S., Russell, J. H. & Ley, T. J. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76, 977–987 (1994).

doi: 10.1016/0092-8674(94)90376-X pubmed: 8137431

Joeckel, L. T., Allison, C. C., Pellegrini, M., Bird, C. H. & Bird, P. I. Granzyme K-deficient mice show no evidence of impaired antiviral immunity. Immunol. Cell Biol. 95, 676–683 (2017).

doi: 10.1038/icb.2017.35 pubmed: 28428612

Saito, S., Murakoshi, K., Kotake, S., Kamatani, N. & Tomatsu, T. Granzyme B induces apoptosis of chondrocytes with natural killer cell-like cytotoxicity in rheumatoid arthritis. J. Rheumatol. 35, 1932–1943 (2008).

pubmed: 18785318

Zhang, D., Beresford, P. J., Greenberg, A. H. & Lieberman, J. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc. Natl Acad. Sci. USA 98, 5746–5751 (2001).

pmcid: 33284 doi: 10.1073/pnas.101329598 pubmed: 11331782

Granzyme serine proteases in inflammation and rheumatic diseases.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Alexandre Aubert (A)

Karen Jung (K)

Sho Hiroyasu (S)

Julian Pardo (J)

David J Granville (DJ)

Classifications MeSH